(KYMR) Kymera Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044

IRAK4, STAT6, TYK2, Protein Degradation

Stock: Biotechnology
Age 5.4y
MCap 5,563m
Avg Vol 756K (56.6M USD)
Beta 1.468
Volatility 66.04%

EPS (Earnings per Share)

EPS (Earnings per Share) of KYMR over the last years for every Quarter: "2020-12": -0.29, "2021-03": -0.29, "2021-06": -0.55, "2021-09": -0.56, "2021-12": -0.66, "2022-03": -0.71, "2022-06": -0.78, "2022-09": -0.79, "2022-12": -0.6, "2023-03": -0.7, "2023-06": -0.67, "2023-09": -0.9, "2023-12": -0.25, "2024-03": -0.62, "2024-06": -0.58, "2024-09": -0.82, "2024-12": -0.89, "2025-03": -0.82, "2025-06": -0.95, "2025-09": -0.94, "2025-12": 0,
EPS CAGR: 37.02%
EPS Trend: 13.1%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of KYMR over the last years for every Quarter: 2020-12: 12.785, 2021-03: 18.702, 2021-06: 18.519, 2021-09: 20.336, 2021-12: 15.275, 2022-03: 9.622, 2022-06: 11.514, 2022-09: 9.551, 2022-12: 16.139, 2023-03: 9.466, 2023-06: 16.513, 2023-09: 4.728, 2023-12: 47.885, 2024-03: 10.287, 2024-06: 25.65, 2024-09: 3.741, 2024-12: 7.394, 2025-03: 22.1, 2025-06: 11.476, 2025-09: 2.764, 2025-12: null,
Rev. CAGR: -36.61%
Rev. Trend: -31.5%
Last SUE: -1.95
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 66.0%
Value at Risk 5%th 95.1%
Relative Tail Risk -12.47%
Reward TTM
Sharpe Ratio 0.94
Alpha 47.74
CAGR/Max DD 0.31
Character TTM
Hurst Exponent 0.628
Beta 1.468
Beta Downside 1.314
Drawdowns 3y
Max DD 71.69%
Mean DD 23.66%
Median DD 19.49%

Description: KYMR Kymera Therapeutics January 11, 2026

Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biotech that builds small-molecule degraders to eliminate disease-causing proteins via the body’s ubiquitin-proteasome system. Its lead pipeline includes a Phase II IRAK4 inhibitor for hidradenitis suppurativa and atopic dermatitis, a STAT6 program targeting type-2 inflammation, and a TYK2 candidate for broader autoimmune indications. Kymera also holds a strategic alliance with Sanofi to co-develop IRAK4 therapeutics outside oncology.

As of the latest filing, Kymera reported a cash runway extending through Q4 2025 and raised roughly $150 million in a 2023 private placement, bolstering its R&D budget. The protein-degradation market is projected to grow at a ~12 % CAGR through 2030, providing a macro-level tailwind for the company’s modality. Within the broader biotechnology sector, peer-group revenue multiples have compressed by ~8 % year-over-year, reflecting heightened scrutiny on cash-burn and milestone-driven pipelines.

For a deeper dive into KYMR’s valuation metrics and peer comparison, you might explore the ValueRay platform.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-295.1m TTM) > 0 and > 6% of Revenue (6% = 2.62m TTM)
FCFTA -0.21 (>2.0%) and ΔFCFTA -6.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1044 % (prev 573.5%; Δ 470.8pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.21 (>3.0%) and CFO -227.9m > Net Income -295.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (87.3m) change vs 12m ago 14.68% (target <= -2.0% for YES)
Gross Margin -83.38% (prev 92.85%; Δ -176.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 4.09% (prev 8.46%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -875.0 (EBITDA TTM -285.9m / Interest Expense TTM 337.0k) >= 6 (WARN >= 3)

Altman Z'' -8.62

(A) 0.41 = (Total Current Assets 528.3m - Total Current Liabilities 71.6m) / Total Assets 1.10b
(B) -0.89 = Retained Earnings (Balance) -979.0m / Total Assets 1.10b
(C) -0.28 = EBIT TTM -294.9m / Avg Total Assets 1.07b
(D) -6.27 = Book Value of Equity -977.5m / Total Liabilities 155.8m
Total Rating: -8.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 31.04

1. Piotroski 0.0pt
2. FCF Yield -4.48%
3. FCF Margin data missing
4. Debt/Equity 0.09
5. Debt/Ebitda 0.10
6. ROIC - WACC (= -37.49)%
7. RoE -33.35%
8. Rev. Trend -31.53%
9. EPS Trend 13.08%

What is the price of KYMR shares?

As of January 21, 2026, the stock is trading at USD 68.14 with a total of 1,024,846 shares traded.
Over the past week, the price has changed by -8.08%, over one month by -19.22%, over three months by +12.63% and over the past year by +55.93%.

Is KYMR a buy, sell or hold?

Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.
  • Strong Buy: 14
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KYMR price?

Issuer Target Up/Down from current
Wallstreet Target Price 116.8 71.4%
Analysts Target Price 116.8 71.4%
ValueRay Target Price 74.8 9.8%

KYMR Fundamental Data Overview January 19, 2026

P/S = 127.2009
P/B = 5.8791
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.14b USD (5.56b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
EV/FCF = -22.33x (Enterprise Value 5.14b / FCF TTM -230.2m)
FCF Yield = -4.48% (FCF TTM -230.2m / Enterprise Value 5.14b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 81.84%)
Tobins Q-Ratio = 4.67 (Enterprise Value 5.14b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.62% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.16% (E(5.56b)/V(5.65b) * Re(11.33%) + D(84.0m)/V(5.65b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: 13.08 | EPS CAGR: 37.02% | SUE: 4.0 | # QB: 1
Revenue Correlation: -31.53 | Revenue CAGR: -36.61% | SUE: -1.95 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.94 | Chg30d=+0.030 | Revisions Net=+3 | Analysts=10
EPS next Year (2026-12-31): EPS=-3.69 | Chg30d=+0.049 | Revisions Net=+8 | Growth EPS=-6.5% | Growth Revenue=-11.2%

Additional Sources for KYMR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle